

Enterprise P&T Meeting Committee July 28, 2025

Voting Members Present

Christopher Antypas, PharmD	Fury Fecondo, PharmD	Jena Quinn, PharmD
Michael Baer, MD	Emily Kryger, PharmD	Manni Sethi, MD
David Batluck, DO	Kelly Martin, PharmD	Christy Skibicki, MD
Tracey Davis, PharmD	Andrew Peterson, PharmD	Rani Whitfield, MD
Rogers Elebra, PharmD	David Petkash, MD	

Excused Voting Members

Donald Beam, MD	Robert Clifford, MD	Lenaye Lawyer, MD	Eric Peters, PharmD
Floyd (John) Brinley, MD	Loretta Dumontet, MD	Yavar Moghimi, MD	Wayne Weart, PharmD
Kirt Caton, MD	Robert Hockmuth, MD	Michelle Murphy, PharmD	

Invited Guests Present

Christian Andreaggi, PharmD	Rajneel Farley, PharmD	Geraldine Marks, PharmD	Ruth Smith, PharmD
Bethany Baird, CPhT	Seema Gupta, MD	Lauren Megargell, PharmD	Luke Stadler, PharmD
Linda Carreras, CPhT	Katherine Harris, PharmD	Christopher Meny, RPh	Lance Vinci, PharmD
Kathleen Clement	Sheireen Huang, PharmD	Patty Oaster	Arlene Wiseman, PharmD
Patrick DeHoratius, PharmD	Amanda Hunter, PharmD	Sarah Pawlak, PharmD	




Issue	Discussion	Conclusion/Results	Action/ Person Responsible
Call to order	The meeting was called to order at 6:01 PM EST	Informational Only	Manni Sethi
 Conflict of Interest Disclosures 	No conflicts announced	Informational Only	Christopher Meny
•			
Review and approval of April P&T Minutes		Committee approved as recommended: Motion: Andrew Peterson	
Old Business		Second: David Batluck	
mResvia AL update	PerformRx makes the following recommendation:	Committee approved as recommended: Motion: David Petkash	PerformRx will update the criteria and formulary/PDL with any changes
	KF.AHC: • Update T3- AL (18 years and older.	Second: Kelly Martin	




6. New Business			
KF.AHC. Vitamin C ALs	PerformRx makes the following recommendation: KF.AHC. • Remove the age limit on the Vitamin C Oral Tablet 250 MG.	Committee approved as recommended: Motion: David Batluck Second: Rani Whitfield	PerformRx will update the criteria and formulary/PDL with any changes
KF.AHC. QL Addition	PerformRx makes the following recommendation: KF.AHC.: • Add Kalydeco 25 mg 60 packets per 30-day supply. • Ivabradine 5 mg: 90 tablets per 30-day supply • Ivabradine 7.5 mg: 60 tablets per 30-day supply	Committee approved as recommended: Motion: David Batluck Second: Rani Whitfield	PerformRx will update the criteria and formulary/PDL with any changes
Complement Inhibitor PA Criteria	PerformRx makes the following recommendation:	Committee approved as recommended: Motion: David Batluck Second: Rani Whitfield	PerformRx will update the criteria and formulary/PDL with any changes

































7. Drug Review			
A. Therapeutic Class:			
Respiratory Aids and Device	PerformRx makes the following recommendation:	Committee approved as recommended: Motion: Christopher Antypas Second: Kelly Martin	No Changes
	KF.AHC.Make no changes to this class.		
Bowel Prep Agents	PerformRx makes the following recommendation:	Committee approved as recommended:	PerformRx will update the criteria and formulary/PDL with any changes





































	 Make no formulary changes. Approve the Chelating Agents prior authorization criteria with the following clinical changes: Update the drug list section to remove Bal in Oil as it has been discontinued. 		
Rho Immune Globulins	PerformRx makes the following recommendation:	Committee approved as recommended:	PerformRx will update the criteria and formulary/PDL with any changes
		Motion: Christopher Antypas Second: Kelly Martin	
	KF.AHC. • Remove the prior authorization for WinRho, Rhophylac, and HyperRHO due		




	to the low utilization and high prior authorization approval rate.		
B. Single Products			
Ctexli	PerformRx makes the following recommendation:	Committee approved as recommended:	PerformRx will update the criteria and formulary/PDL with any changes
		Motion: David Batluck Second: Tracey Davis	
	KF/AHC/Maintain Ctexli as T4 with a prior authorization requirement.		















































Camzyos	PerformRx makes the following recommendation:	Committee approved as recommended:	PerformRx will update the criteria and formulary/PDL with any changes
Jan. 12, 100		Motion: Christopher Antypas	
		Second: Andrew Peterson	
		:	
	_		
	'		
	 KF.AHC. Update the initial authorization section 		
	to reflect the updated contraindications		
	section of the Camzyos package insert		
	·		



































































	KF.AHC.: • Approve the Duvyzat prior authorization criteria with no clinical changes.		
Elevidys	PerformRx makes the following recommendation: KF.AHC. Approve the Elevidys prior authorization criteria with no clinical changes.	Committee approved as recommended: Motion: Christopher Antypas Second: Andrew Peterson *Manni Sethi & Christopher Antypas: spoke regarding the fatality. *Will keep up with future updates.	No Changes
	PerformRx makes the following recommendation:	Committee approved as recommended:	No Changes
































	Thyroid Eye Disease prior authorization criteria with no clinical changes.		
Joenja	PerformRx makes the following recommendation: KF.AHC: Approve the Joenja prior authorization criteria with no clinical changes.	Committee approved as recommended: Motion: Christopher Antypas Second: Andrew Peterson	No Changes
















































	PerformRx makes the following	Committee approved as	
Verquvo	recommendation:	recommended:	No Changes
		Motion: Christopher Antypas	
	—	Second: Andrew Peterson	
	KF.AHC.:		
	 Approve the Verquvo prior authorization criteria with no clinical changes. 		
Vijoice	PerformRx makes the following recommendation:	Committee approved as recommended:	No Changes
Vijoloc			No changes
		Motion: Christopher Antypas Second: Andrew Peterson	















10. Recalls	Date: 7/15/2025			
	Manufacturer: Nostrum Laboratories, Inc.			
	Product Name: Sucralfate Tablets USP 1 Gram			
	Reason: Company closure and discontinuation of quality activities.			
11. Adjourn	The meeting adjourned at 7:07 PM EST	Manni Sethi		
	Motion: Kelly Martin Second: Rani Whitfield			
	Next P&T Meeting			
	October 27th, 2025 6:00pm- 8:00pm EST			
•	oloopiii oloopiii Loi			



Signed: January Market Prompt

Date: 10/27/2025